Cargando…
The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
The tumor suppressor protein p53 is mutated in close to 50% of human tumors and is dysregulated in many others, for instance by silencing or loss of p14(ARF). Under steady-state conditions, the two E3 ligases MDM2/MDM4 interact with and inhibit the transcriptional activity of p53. Inhibition of p53–...
Autores principales: | Ingelshed, Katrine, Spiegelberg, Diana, Kannan, Pavitra, Påvénius, Linnéa, Hacheney, Jessica, Jiang, Long, Eisinger, Silke, Lianoudaki, Danai, Lama, Dilraj, Castillo, Francisca, Bosdotter, Cecilia, Kretzschmar, Warren W., Al-Radi, Omayma, Fritz, Nicolas, Villablanca, Eduardo J., Karlsson, Mikael C. I., Wermeling, Fredrik, Nestor, Marika, Lane, David P., Sedimbi, Saikiran K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010373/ https://www.ncbi.nlm.nih.gov/pubmed/36922937 http://dx.doi.org/10.1158/2767-9764.CRC-22-0053 |
Ejemplares similares
-
MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia
por: Lerma Clavero, Ada, et al.
Publicado: (2023) -
CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
por: Jiang, Long, et al.
Publicado: (2022) -
CD36 and LC3B initiated autophagy in B cells regulates the humoral immune response
por: He, Chenfei, et al.
Publicado: (2021) -
S207: NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELOPROLIFERATIVE NEOPLASM-BLAST PHASE (MPN-BP) INITIATING CELLS AND PROLONGS LEUKEMIA-FREE SURVIVAL (LFS) IN AN MPN-BP PDX MODEL
por: Wang, Xiaoli, et al.
Publicado: (2023) -
Combined proinflammatory cytokine and cognate activation of invariant natural killer T cells enhances anti-DNA antibody responses
por: Sedimbi, Saikiran K., et al.
Publicado: (2020)